Compare DTM & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTM | BBIO |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 12.7B |
| IPO Year | 2021 | 2019 |
| Metric | DTM | BBIO |
|---|---|---|
| Price | $150.10 | $67.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 25 |
| Target Price | ★ $142.82 | $86.33 |
| AVG Volume (30 Days) | 725.5K | ★ 2.9M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 19.44 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $1,243,000,000.00 | $502,076,000.00 |
| Revenue This Year | $7.56 | $89.45 |
| Revenue Next Year | $5.98 | $73.78 |
| P/E Ratio | $119.11 | ★ N/A |
| Revenue Growth | 26.71 | ★ 126.26 |
| 52 Week Low | $98.06 | $31.77 |
| 52 Week High | $151.79 | $84.94 |
| Indicator | DTM | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 66.30 | 46.10 |
| Support Level | $129.62 | $62.37 |
| Resistance Level | $150.45 | $69.22 |
| Average True Range (ATR) | 2.74 | 2.93 |
| MACD | 0.18 | 0.27 |
| Stochastic Oscillator | 76.22 | 51.79 |
DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates maximum revenue from pipeline segment that includes interstate pipelines, storage systems, gathering lateral pipelines and compression and surface facilities.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.